Congress Asset Management Co. MA Purchases 86,293 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Congress Asset Management Co. MA boosted its position in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 17.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 594,672 shares of the medical instruments supplier’s stock after purchasing an additional 86,293 shares during the quarter. Congress Asset Management Co. MA owned approximately 2.66% of LeMaitre Vascular worth $33,754,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. DekaBank Deutsche Girozentrale bought a new position in LeMaitre Vascular in the third quarter worth $38,000. SRS Capital Advisors Inc. raised its holdings in LeMaitre Vascular by 325.5% in the fourth quarter. SRS Capital Advisors Inc. now owns 685 shares of the medical instruments supplier’s stock worth $39,000 after purchasing an additional 524 shares in the last quarter. Personal CFO Solutions LLC raised its holdings in LeMaitre Vascular by 6.4% in the fourth quarter. Personal CFO Solutions LLC now owns 5,574 shares of the medical instruments supplier’s stock worth $316,000 after purchasing an additional 336 shares in the last quarter. KLR Investment Advisors LLC bought a new position in LeMaitre Vascular in the fourth quarter worth $351,000. Finally, Riverwater Partners LLC raised its holdings in LeMaitre Vascular by 2.5% in the fourth quarter. Riverwater Partners LLC now owns 8,216 shares of the medical instruments supplier’s stock worth $466,000 after purchasing an additional 198 shares in the last quarter. Institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Price Performance

NASDAQ LMAT traded up $1.04 during trading hours on Friday, hitting $80.09. The company’s stock had a trading volume of 100,490 shares, compared to its average volume of 99,054. LeMaitre Vascular, Inc. has a 12 month low of $44.27 and a 12 month high of $81.68. The company’s 50 day simple moving average is $73.01 and its two-hundred day simple moving average is $64.77. The company has a market cap of $1.80 billion, a P/E ratio of 53.04, a price-to-earnings-growth ratio of 2.44 and a beta of 0.89.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings results on Thursday, May 2nd. The medical instruments supplier reported $0.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.39 by $0.05. The business had revenue of $53.48 million during the quarter, compared to the consensus estimate of $51.50 million. LeMaitre Vascular had a return on equity of 11.57% and a net margin of 16.99%. The business’s quarterly revenue was up 13.6% compared to the same quarter last year. During the same period in the previous year, the company posted $0.27 EPS. As a group, research analysts predict that LeMaitre Vascular, Inc. will post 1.77 earnings per share for the current fiscal year.

LeMaitre Vascular Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, May 30th. Shareholders of record on Thursday, May 16th were paid a dividend of $0.16 per share. The ex-dividend date of this dividend was Wednesday, May 15th. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.80%. LeMaitre Vascular’s dividend payout ratio is currently 42.38%.

Insider Buying and Selling at LeMaitre Vascular

In related news, CEO George W. Lemaitre sold 8,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 8th. The stock was sold at an average price of $75.30, for a total transaction of $602,400.00. Following the completion of the transaction, the chief executive officer now directly owns 2,079,128 shares in the company, valued at approximately $156,558,338.40. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, CEO George W. Lemaitre sold 68,906 shares of the business’s stock in a transaction that occurred on Monday, May 6th. The stock was sold at an average price of $75.70, for a total transaction of $5,216,184.20. Following the completion of the transaction, the chief executive officer now directly owns 2,133,428 shares in the company, valued at approximately $161,500,499.60. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO George W. Lemaitre sold 8,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 8th. The stock was sold at an average price of $75.30, for a total value of $602,400.00. Following the completion of the transaction, the chief executive officer now directly owns 2,079,128 shares in the company, valued at $156,558,338.40. The disclosure for this sale can be found here. Insiders sold a total of 87,431 shares of company stock worth $6,627,520 in the last three months. 10.79% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

LMAT has been the subject of several recent analyst reports. Stifel Nicolaus raised LeMaitre Vascular from a “hold” rating to a “buy” rating and lifted their price target for the stock from $59.00 to $75.00 in a research report on Friday, April 26th. StockNews.com raised LeMaitre Vascular from a “hold” rating to a “buy” rating in a research report on Friday. Barrington Research lifted their price target on LeMaitre Vascular from $69.00 to $79.00 and gave the stock an “outperform” rating in a research report on Friday, May 3rd. JMP Securities lifted their price target on LeMaitre Vascular from $72.00 to $77.00 and gave the stock a “market outperform” rating in a research report on Friday, May 3rd. Finally, Roth Capital raised LeMaitre Vascular to a “strong-buy” rating in a research report on Friday, May 31st. Two analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $77.57.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.